Literature DB >> 15261431

Pathology of malignant mesothelioma.

Eric Van Marck1.   

Abstract

The diagnosis of malignant mesothelioma relies firstly on the identification of the mesothelial nature of the neoplastic cell and secondly on the demonstration of the invasive properties of the proliferation. The latter aspect cannot be achieved by studying cellular material yet, in the right clinical setting, it is often possible to make a presumptive diagnosis of malignant mesothelioma based on exudates. Differentiation between mesothelial hyperplasia and metastatic adenocarcinoma by cytological examination alone is unreliable, so further evidence can be gathered from techniques such as histopathology, histochemistry and electron microscopy. Immunohistochemistry aims to confirm the mesothelial nature of the neoplastic cells while ruling out metastatic lesions. At present there is no single reliable marker for neoplastic mesothelioma, although evidence has been presented on a large variety of gene products. In an attempt to differentiate between hyperplastic mesothelium and malignant mesothelioma, Dhaene has been able to show that over 90% of malignant mesotheliomas show telomerase activity and express telomerase subunits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261431     DOI: 10.1016/j.lungcan.2004.04.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  1 in total

1.  Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.

Authors:  S T Lee; M Ghanem; R A Herbertson; S U Berlangieri; A J Byrne; K Tabone; P Mitchell; S R Knight; M Feigen; A M Scott
Journal:  Mol Imaging Biol       Date:  2009-03-28       Impact factor: 3.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.